Compugen Goes for Dual Listing on the Tel Aviv Stock Exchange | GenomeWeb

NEW YORK, Dec. 26 – Compugen, an Israeli bioinformatics company that trades on the Nasdaq stock exchange, said Wednesday that it had received approval to list its shares on the Tel Aviv Stock Exchange.

The move towards a dual listing is aimed at increasing interest in Compugen’s stock by providing easier access for investors in Israel to trade the company’s shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.